These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38831665)

  • 1. Adherence and Treat-to-Target Benchmarks in Older Adults With Gout Initiating Urate-Lowering Therapy in Ontario, Canada: A Population-Based Study.
    Kwok TSH; Kuriya B; Hawker G; Eder L; Li P; Choy G; Widdifield J
    Arthritis Care Res (Hoboken); 2024 Oct; 76(10):1379-1389. PubMed ID: 38831665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Urate Monitoring Among Older Adults With Gout: Initiating Urate-Lowering Therapy in Ontario, Canada.
    Kwok TSH; Kuriya B; Hawker G; Li P; Choy G; Widdifield J
    Arthritis Care Res (Hoboken); 2023 Dec; 75(12):2463-2471. PubMed ID: 37248652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
    Quilisadio JEC; Salido EO; Penserga EG
    Mod Rheumatol; 2021 May; 31(3):755-761. PubMed ID: 32701037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
    Juraschek SP; Kovell LC; Miller ER; Gelber AC
    Arthritis Care Res (Hoboken); 2015 Apr; 67(4):588-92. PubMed ID: 25201123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Gout Flares With the Initiation of Treat-to-Target Allopurinol and Febuxostat: A Post-Hoc Analysis of a Randomized Multicenter Trial.
    Barry A; Helget LN; Androsenko M; Wu H; Kramer B; Newcomb JA; Brophy MT; Davis-Karim A; England BR; Ferguson R; Pillinger MH; Neogi T; Palevsky PM; Merriman TR; O'Dell JR; Mikuls TR
    Arthritis Rheumatol; 2024 Oct; 76(10):1552-1559. PubMed ID: 38925627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
    Jackson RL; Hunt B; MacDonald PA
    BMC Geriatr; 2012 Mar; 12():11. PubMed ID: 22436129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
    Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
    Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout.
    Hughes JC; Wallace JL; Bryant CL; Salvig BE; Fourakre TN; Stone WJ
    Ann Pharmacother; 2017 Apr; 51(4):301-306. PubMed ID: 27881692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
    Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
    Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study.
    Steelandt A; Hittinger A; Kanagaratnam L; Kazes I; Clavel P; Bolko L; Rieu P; Salmon JH
    BMC Nephrol; 2024 Aug; 25(1):266. PubMed ID: 39164615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
    Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
    BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.
    Janssen CA; Oude Voshaar MAH; Vonkeman HE; Krol M; van de Laar MAFJ
    Clin Rheumatol; 2018 Aug; 37(8):2291-2296. PubMed ID: 29721712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data.
    Koto R; Nakajima A; Horiuchi H; Yamanaka H
    Pharmacoepidemiol Drug Saf; 2021 Feb; 30(2):157-168. PubMed ID: 32939919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of adherence to urate-lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient-reported dosing.
    Schulz M; Coleshill MJ; Day RO; Wright DFB; Brett J; Briggs NE; Aung E
    Br J Clin Pharmacol; 2024 May; 90(5):1322-1332. PubMed ID: 38382554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
    Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
    Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.
    Janssen CA; Jansen TLTA; Oude Voshaar MAH; Vonkeman HE; van de Laar MAFJ
    Rheumatol Int; 2017 Sep; 37(9):1435-1440. PubMed ID: 28748426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
    Liang N; Sun M; Sun R; Xu T; Cui L; Wang C; Ma L; Cheng X; Xue X; Sun W; Yuan X; Zhang H; Li H; He Y; Ji A; Wu X; Li C
    Arthritis Res Ther; 2019 Sep; 21(1):200. PubMed ID: 31477161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.